OncoCyte Corporation is primarily focused on the development of novel, non-invasive blood and urine diagnostic tests for detection of cancer. OncoCyte Corporation is based in Alameda, California.
| Revenue (Most Recent Fiscal Year) | $1.88M |
| Net Income (Most Recent Fiscal Year) | $-60.66M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 24.26 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 9.12 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -1514.57% |
| Net Margin (Trailing 12 Months) | -1516.06% |
| Return on Equity (Trailing 12 Months) | -215.59% |
| Return on Assets (Trailing 12 Months) | -27.23% |
| Current Ratio (Most Recent Fiscal Quarter) | 3.74 |
| Quick Ratio (Most Recent Fiscal Quarter) | 3.70 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.20 |
| Inventory Turnover (Trailing 12 Months) | 6.62 |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.36 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.26 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.45 |
| Diluted Earnings per Share (Trailing 12 Months) | $-3.53 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Common Shares Outstanding | 28.60M |
| Free Float | 28.01M |
| Market Capitalization | $93.23M |
| Average Volume (Last 20 Days) | 0.04M |
| Beta (Past 60 Months) | 0.95 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 2.05% |
| Percentage Held By Institutions (Latest 13F Reports) | 55.35% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |